Clinical Trial Search

Primary: Number of Participants With Solicited Administration-site Events After the First Vaccination — 3; 11; 20; 22 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388 — 5; 5; 5; 8 Participants

Primary: Cmax: Maximum Observed Plasma Concentration for Brigatinib — 366.6; 397.6 nanogram per millliliter (ng/mL)

Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants

Primary: Area Under the Plasma Concentration Versus Time Curve of Moxidectin. — 2680; 2230; 3310; 1880 (hr*ng/mL)/mg

Primary: Verified Detection Rate for Metastasis — 5.9; 5.5 SUVMax

Primary: The Participant Incidence of Treatment-emergent Adverse Events Considered by the Investigator as Related to ELI-002 — 1; 3; 2; 2 Participants

Primary: Safety and Tolerability Evaluated on Treatment Emergent Adverse Events — 4; 6; 9; 4 participants

Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 6; 4; 1 Participants

Primary: Weight — -6; -3; -5; -4 Lbs

Primary: Participant With Treatment Emergent Adverse Events (TEAEs) — 2; 3; 1 Participants

Primary: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) — 1; 0; 0; 3 Participants

Primary: Number of Participants With One or More Treatment-Emergent Adverse Event(s) (TEAEs) — 4; 8; 8; 7 Participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Number of Participants With One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to…